AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, AstraZeneca AB, KuDOS Pharmaceuticals Limited, The University of Sheffield, and MSD International Business GmbH (hereinafter collectively "AstraZeneca"), and Sandoz Inc. (hereinafter "Sandoz"), the parties in the above-captioned actions, which have been consolidated for pretrial purposes under docket number 3:23-796 (the "796 Matter"), have agreed to terms and conditions representing a negotiated settlement of these actions and have set forth those terms and conditions in a Settlement Agreement (the "Settlement Agreement"). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in the actions, as follows: 1. day of April, 2026: ORDERED, ADJUDGED AND DECREED as follows: As used in this Consent Judgment, (i) the term "Sandoz Product" shall mean the drug product sold, offered for sale or distributed pursuant to Abbreviated New Drug Application No. 217936; (ii) the term "Licensed Patents" shall mean United States Patent Numbers 8,475,842, 8,859,562, 11,633,396, 11,975,001, 12,048,695, 12,144,810, and 12,178,816; and (iii) the term "Affiliate" shall mean any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Sandoz; for purposes of this definition, "control" means (a) ownership, directly or through one or more intermediaries, of (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity. 2. 3. 4. All claims, counterclaims, affirmative defenses and demands in this action Unless otherwise specifically authorized pursuant to the Settlement Agreement, Sandoz, including any of its Affiliates, successors and assigns, is enjoined from infringing the Licensed Patents, on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing or distributing of the Sandoz Product. Compliance with this Consent Judgment may be enforced by AstraZeneca and its successors in interest, or assigns. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment. 5. with respect to the Sandoz Product are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party. Please note that the filing of this Consent Judgment Judgement in the 796 Matter reflects resolution of that action only between Plaintiffs and Sandoz. The matters against Natco Pharma Limited, Cipla Limited, Cipla USA, Inc., Zydus Pharmaceuticals (USA) Inc., and the 79 Matra atpstill actny .. Zydus Lifesciences Ltd, that were consolidated and maintained in the 796 Matter are still active.